One of the less visible—but highly valuable—layers of ZP’s wearable microneedle portfolio lies not just in how we access the body, but in how we interpret and act on the data we collect. This patent exemplifies that approach. It describes an intelligent monitoring system that dynamically adapts how often measurements are taken based on physiological risk, increasing measurement frequency only when an analyte such as glucose approaches clinically meaningful thresholds. The result is faster, more reliable detection of true health events while dramatically reducing false or nuisance alerts.
In practical terms, this means a wearable microneedle system that stays energy-efficient and unobtrusive during normal conditions, but becomes highly responsive when the wearer’s physiology demands it. By confirming alerts through multiple rapid measurements before notifying the user or connected devices, the system avoids alarm fatigue while still ensuring timely intervention when it matters most. This balance between discretion, reliability, and safety is essential for real-world adoption of continuous monitoring technologies.
Importantly, this patent is not a standalone idea—it is part of ZP’s broader IP moat around wearable microneedle platforms. It complements ZP’s protected innovations in minimally invasive microneedle sensing, wearable integration, and system architecture, extending protection beyond the physical interface into the intelligence layer that governs performance, usability, and clinical relevance. For partners, this translates into more than a sensor: it offers access to a defensible, end-to-end technology stack that combines hardware, software, and data logic into a single, collaboration-ready platform.
